Co-occurring Challenges: Leveraging ADAP and ACA to Address Hepatitis C and Substance Use Disorders Daniel Raymond Policy Director Harm Reduction Coalition.

Slides:

Advertisements

Similar presentations

Mady Chalk, PhD., MSW Treatment Research Institute November, 2013.

Advertisements

Specific issues and guidelines for HCV treatment in IDUs Bern d Schulte Centre for Interdisciplinary Addiction Research (CIAR), University Hamburg.

Out of Sight, Out of Time: Injection Drug Users, Hepatitis C, and HIV Policy Daniel Raymond Hepatitis C Policy Analyst Harm Reduction Coalition

Hepatitis C and You  2014 Greenview Hepatitis C Fund All Rights Reserved.

DAN BELNAP LEGAL ACTION CENTER FAMILIES USA HEALTH ACTION CONFERENCE JANUARY 25, 2014 Mental Health/Substance Use Disorder Parity: Improving Access to.

Treatment Of Medical, Psychiatric, and Substance Use Co-morbidities In People Infected With HIV Who Use Drugs Frederick L. Altice (US, Malaysia, Ukraine)

HIV and Hepatitis C in non- MSM Rural Communities: Issues and Interventions Shari Wells-Weiss, CASAC Director of Prevention Services Southern Tier AIDS.

Senate Health Care Committee Briefing: Hepatitis C Treatment Dan Lessler, MD Chief Medical Officer November 20, 2014.

HIV/AIDS and Substance Use Disorders Olivera J. Bogunovic, M.D. State University of New York at Buffalo Alcohol Medical Scholars Program.

Global Hepatitis C Guidelines 2014: recommendations for a public health approach Gottfried Hirnschall.

Hepatitis and Liver Cancer A National Strategy for Prevention and Control of Hepatitis B and C.

A View From the Ground Better Care at Lower Cost for High Risk Patients.

Management of Hepatitis C: An Unprecedented Challenge for Corrections Brad Livingston Executive Director, Texas Department of Criminal Justice Lannette.

 Professional society founded in 1954 representing 3,100+ physicians & other associated professionals  Mission:  Increase access to & improve the quality.

HIV and Behavioral Health: An Update from SAMHSA Elinore F. McCance-Katz, MD, PhD Chief Medical Officer Substance Abuse and Mental Health Services Administration.

F/C AETC Faculty HIV HCV Thursday, March 12, 2015 | 1:30pm EDT Medical Facilitator/Didactic Presenter Todd S. Wills, MD University of South Florida Case.

Increase access to care for individuals and families, including criminal justice-involved populations, many of whom may be newly-eligible for Medi-Cal.

The AIDS Institute The Impact of Essential Health Benefits on People Living with HIV/AIDS Carl Schmid Deputy Executive Director ADAP Advocacy Association.

Larry Cuellar Adult Viral Hepatitis Prevention Coordinator Texas Department of State Health Services 2010 STREET OUTREACH WORKERS CONFERENCE June 21, 2010.

Integrated Health Home Services in an Opioid Treatment Program: A Model Yngvild Olsen, MD, MPH Institutes for Behavior Resources, Inc./REACH Health Services.

Abstract Results Objectives Results Conclusions Background Methods V-1637 Background-At the CORE center in Chicago, despite an on-site hepatitis clinic.

HEPATITIS C TREATMENT EXPANSION INITIATIVE ETAC Project Summary Webinar May 28, 2014 The HRSA/SPNS Hepatitis C Treatment Expansion Initiative: Project.

Healthcare Reform The “Affordable Care Act” How Will It Affect Substance Abuse Care?

1 Nassau County Heroin Treatment Task Force Tracie M. Gardner Director of NYS Policy December 7, 2012.

Mission: Protect the Vulnerable, Promote Strong and Economically Self- Sufficient Families, and Advance Personal and Family Recovery and Resiliency. Charlie.

A global perspective on scaling up harm reduction 2 nd National Harm Reduction Conference, Ukraine, March 2007 Dr Jos Perriens, Director Prevention.

Missed opportunities to diagnose TB and HIV Co-infection in HIV workplace program Dr Fred Mugyenyi Asiimwe Medical Director, ALAFA.

NURSETRI, Nursing role in HIV care : an overview Jane Bruton Clinical Research Nurse.

ANDROMEDA TRANSCULTURAL HEALTH RICARDO GALBIS, M.D. Executive Director MAY 20, Decatur Street NW Washington, DC

STD Control Branch Addressing HCV through a Drug User Health Framework NASTAD Viral Hepatitis Technical Assistance Meeting, October 21, 2014 Washington,

Olivia Chang, MPH Research and Program Manager Pangaea Global AIDS

Coverage and Management of Medications for Treating Substance Abuse in Health Plans Constance M. Horgan, Sc.D. Sharon Reif, Ph.D. Dominic Hodgkin, Ph.D.

Pennsylvania: The State of HCV 2015

‘Gaps in the global HIV/AIDS success story Copenhagen December 2 nd 2013 Gaps in the global HIV/AIDS success story Briefing on HIV/AIDS in Europe Martin.

Injection Drug Use and Hepatitis C What Can We Do About It? Wilson M. Compton, M.D., M.P.E. Deputy Director National Institute on Drug Abuse.

National Policy Update October 15, 2015 Chuck Ingoglia, MSW.

Suppressing the Hepatitis C virus, Barriers to Care American Public Health Association APHA 143 rd Annual Meeting&Expo October 31-November 4,2015, Chicago,

Special patient groups Module 5. Introduction Worldwide, the majority of people in substitute treatment are men between Even they do not form a.

1 Performance Measurement for Medication-Assisted Treatment with Buprenorphine: Translating Evidence-Based Practices Such as Medication- Assisted Treatment.

TRI science addiction Implementing the IOM Report: The TRI-State Policy Program ACADEMY HEALTH Mady Chalk, Ph.D. Treatment Research Institute June, 2006.

S L I D E 0 Enhanced Uptake of Hepatitis C Treatment in an Opioid Treatment Program in the Direct Acting Antiviral Era Jenna Butner MD 1,2, Julia Shi MD.

Accessibility, Pattern of Use and Implications of Restricted Availability of Medicines for Treatment of Substance Abuse in a Tertiary Level Health Care.

Gabrielle de la Guéronnière, Legal Action Center 2014 RSAT Grantee Meeting July 18, 2014 The Affordable Care Act and the Criminal Justice System: Huge.

Behavioral Health – Primary Care Integration. Odyssey House Overview Established in 1971 Integrated System of Care Substance Use Disorder Treatment Psychiatric.

Medical Assisted Treatment

Medication Assisted Treatment

Treatment Access A Substance Use Disorder Perspective

Where Are We on the Path to Elimination of Chronic Hepatitis C?

Medicaid Coverage of Pharmaceuticals Life Science Tennessee

A Providers Perspective: Management and Treatment of HCV in PWID

Addressing Viral Hepatitis

Addressing the Intersection of Substance Abuse and Viral Hepatitis

COLLECTIVE IMPACT APPROACH TO ADDRESSING

Lesson 4: Test Your Knowledge

Substance Use Disorders in People Living with HIV

HIV/HCV Co-Infection Case

Talking to Patients About HCV Treatment

Nick Szubiak, MSW, LCSW Director, Clinical Excellence in Addictions

Tuerk Conference, Baltimore, MD April 20, 2018

Implementing and Monitoring Parity

Gabrielle de la Guéronnière, Legal Action Center September 27, 2017

What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?

ENDING THE EPIDEMICS: A FOCUS ON PEOPLE WHO INJECT DRUGS

The HRSA/SPNS Hepatitis C Treatment Expansion Initiative: Project Summary Webinar for Demonstration Clinics.

Vice President for Health Initiatives

Vision Transformative collaboration that fosters resilient self-sustaining Recovery Communities. Mission To develop and sustain measurable solutions that.

Alcohol, Other Drugs, and Health: Current Evidence

No conflicts of interest

Lesson 3: The HCV Care Continuum

Transforming the Delivery of Substance Use Disorder Treatment in States Update August 2019.

Presentation transcript:

Co-occurring Challenges: Leveraging ADAP and ACA to Address Hepatitis C and Substance Use Disorders Daniel Raymond Policy Director Harm Reduction Coalition

Challenges Hepatitis C co-infection is a leading cause of mortality in people living with HIV/AIDS Substance use disorders magnify gaps in the HIV Care Continuum ARV access is necessary but not sufficient

Hepatitis C Co-infection Roughly 25% of HIV+ in United States co- infected with chronic HCV HIV co-infection worsens HCV outcomes, and HCV-related liver disease is a leading cause of non-AIDS-related death in PLWHA New HCV treatments are increasingly effective and well-tolerated

Substance Use Disorders Substance use disorders are highly prevalent among PLWHA Untreated SUDs impede linkage & retention in care, receipt of ARV, and adherence An estimated 25% of PLWHA are in need of treatment for an alcohol or substance use disorder

Medications of Interest Current HCV regimens: Genotype 1: Sovaldi/PEG/RBV, Olysio/PEG/RBV, Sovaldi/Olysio +/- RBV, Sovaldi/RBV Genotype 2/3: Sovaldi/RBV Medication-assisted treatment for opioid use disorders: methadone, buprenorphine, naltrexone

Role of ADAP: Direct Purchase Limited coverage of HCV direct-acting antivirals: in 2012, only 8 states covered telaprevir and/or boceprevir (roughly half covered pegylated interferon) Extremely limited coverage of methadone and/or buprenorphine

Role of ADAP: Insurance Support (premiums/cost-sharing) HCV direct-acting antivirals: dynamic environment as new regimens enter market Payer resistance re: cost of new drugs, volume of potential patient population HCV drugs typically under PA requirements, higher specialty tiers Concerns re: clinical criteria, fail first/step therapy

Role of ADAP: Insurance Support (premiums/cost-sharing) 2013 ASAM report on MAT coverage Medicaid: incomplete coverage (17 states don’t cover methadone; majority require PA for buprenorphine; lifetime/dosage limits) Commercial plans: methadone typically not covered; buprenorphine subject to PA, dosage limits, specialty tier, other restrictions

ADAP/ACA Interaction How to guarantee access & affordability for HCV treatment & MAT for opioid use disorders? Monitor plan design (formulary & network) for care & coverage Track utilization & barriers to access Understand protections (discrimination; Mental Health Parity & Addiction Equity Act)

Additional resources NASTAD ADAP Monitoring Project Project%20Annual%20Report AASLD/IDSA Hepatitis C Treatment Guidance ASAM Advancing Access to Addiction Medications